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Abstract
Background: Luteinizing hormone secreted by the anterior pituitary gland regulates gonadal
function. Luteinizing hormone secretion is regulated both by alterations in gonadotrope
responsiveness to hypothalamic gonadotropin releasing hormone and by alterations in
gonadotropin releasing hormone secretion. The mechanisms that determine gonadotrope
responsiveness are unknown but may involve regulators of G protein signaling (RGSs). These
proteins act by antagonizing or abbreviating interaction of Gα  proteins with effectors such as
phospholipase Cβ . Previously, we reported that gonadotropin releasing hormone-stimulated
second messenger inositol trisphosphate production was inhibited when RGS3 and gonadotropin
releasing hormone receptor cDNAs were co-transfected into the COS cell line. Here, we present
evidence for RGS3 inhibition of gonadotropin releasing hormone-induced luteinizing hormone
secretion from cultured rat pituitary cells.
Results: A truncated version of RGS3 (RGS3T = RGS3 314–519) inhibited gonadotropin releasing
hormone-stimulated inositol trisphosphate production more potently than did RSG3 in
gonadotropin releasing hormone receptor-bearing COS cells. An RSG3/glutathione-S-transferase
fusion protein bound more 35S-Gqα  than any other member of the G protein family tested.
Adenoviral-mediated RGS3 gene transfer in pituitary gonadotropes inhibited gonadotropin
releasing hormone-stimulated luteinizing hormone secretion in a dose-related fashion. Adeno-
RGS3 also inhibited gonadotropin releasing hormone stimulated 3H-inositol phosphate
accumulation, consistent with a molecular site of action at the Gqα  protein.
Conclusions:  RGS3 inhibits gonadotropin releasing hormone-stimulated second messenger
production (inositol trisphosphate) as well as luteinizing hormone secretion from rat pituitary
gonadotropes apparently by binding and suppressing the transduction properties of Gqα  protein
function. A version of RGS3 that is amino-terminally truncated is even more potent than intact
RGS3 at inhibiting gonadotropin releasing hormone-stimulated inositol trisphosphate production.
Published: 7 November 2001
BMC Cell Biology 2001, 2:21
Received: 20 April 2001
Accepted: 7 November 2001
This article is available from: http://www.biomedcentral.com/1471-2121/2/21
© 2001 Neill et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commer-
cial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact info@biomedcentral.comBMC Cell Biology 2001, 2:21 http://www.biomedcentral.com/1471-2121/2/21
Background
A near-universal feature of cell signaling via seven trans-
membrane, G protein-coupled receptors is attenuation
of a cellular response upon prolonged exposure to an ex-
tracellular stimulus [1]. This desensitization process is
well-established for GnRH-stimulated LH secretion
from pituitary gonadotropes [2,3], and occurs after
about 6 h of continued exposure to GnRH in rats [3]; re-
moval of GnRH permits recovery from the profound sup-
pression of LH secretion, albeit rather slowly (2–4 days;
4). The molecular mechanisms involved in GnRH-in-
duced desensitization are poorly understood, but they do
not appear to be due to alterations in GnRH receptor ex-
pression [5,6] or to changes in LH concentrations in the
pituitary gland [7,8].
Earlier, we presented evidence that a regulator of G pro-
tein signaling, RGS3, might participate in the regulation
of GnRH receptor signaling [9]. The mechanism of RGS
action is antagonism of the Gα  protein either by acceler-
ating its hydrolysis of GTP, thereby prematurely termi-
nating signaling due to reassociation of the Gα  and Gβγ
complexes [10], or by antagonizing interaction of the Gα
protein with its effector such as phospholipase Cβ
[11,12]. A large number of RGS genes have been identi-
fied in mammals based on the presence of a 120 amino
acid core domain [13–16]. RGS proteins have been de-
scribed that interact with the Giα  and Gqα  members of
the G protein family [17–21].
Previously, we showed that RSG3 was expressed endog-
enously in rat pituitary cells and, when experimentally
co-expressed together with GnRH receptors in a heterol-
ogous cell line (COS1), it suppressed GnRH-stimulated
inositol trisphosphate production [9]. Here, those stud-
ies have been extended to include GnRH-stimulated LH
secretion using adenovirus-mediated gene transfer of
RGS3 complementary DNA into normal rat pituitary go-
nadotropes. RGS3 was found to profoundly inhibit
GnRH-stimulated LH secretion and 3H-inositol phos-
phate accumulation. However, a calcium ionophore
stimulated LH secretion in RGS3-expressing gonado-
tropes, confirming a specific site of action occurring at
phospholipase Cβ  or earlier in the signal transduction
pathway.
Results
The initial experiments were performed to confirm our
earlier finding that RGS3 suppressed GnRH-stimulated
IP3 production in COS-1 cells [9] and to test a truncated
form of RGS3, RGS3T (RGS3 314–519) [24] for suppres-
sive activity in the same assay (Fig. 1). cDNAs represent-
ing the GnRH receptor and RGS3 or RGS3T were co-
transfected into COS-1 cells for GnRH-A treatment 72 h
later; intracellular IP3 concentrations were measured at
0, 10, 20, and 30 sec after addition of 10-7M GnRH-A
(Fig. 1). As expected, RGS3 exerted a profound suppres-
sion of IP3 production at each of the time points during
the 30 sec after agonist treatment (p < 0.05) (Fig. 1).
RGS3T is comprised primarily by the consensus RGS do-
main and was originally reported to decrease the growth
rate of yeast and to inhibit IL-8 receptor mediated acti-
vation of MAP kinase by a factor of 3–10 fold as com-
pared to RGS3 [24] and was subsequently reported to be
a normally expressed variant of RGS3 [37]. Therefore,
we compared it to RGS3 for attenuation of GnRH-stimu-
lated IP3 production in COS-1 cells (Fig. 1). As reported
by others [24,37], we found that RGS3T was more potent
than RGS3 (p < 0.05) (Fig. 1). Identification of a C-termi-
nal 205 amino acid variant of RGS3 that has equal or
greater potency than the full-length 519 amino acid
RGS3 will facilitate the identification of RGS3 functional
protein domains that are important for its activity.
The family of RGS proteins are established to interact
with various Gα -protein subunits, thereby antagonizing
their activities [13–18,24]. Indeed, we previously report-
ed that RGS3 bound Gqα  [9], the G protein subunit that
mediates GnRH receptor signaling [38]. Here, we have
extended those binding studies to include other Gα  pro-
Figure 1
RGS3 and RGS3T suppress GnRH-stimulated IP3 concentra-
tions in COS-1 cells. The cells were co-transfected with
cDNAs representing the GnRH receptor and RGS3 or
RGS3T; 72 h later the cells were treated with 10-7M GnRH
for 0, 10, 20, or 30 sec before being collected for IP3 meas-
urements using receptor radioassay in which IP3 and 3H-IP3
competed for binding to IP3 receptors prepared from calf
cerebellum. Data presented are the mean ± SEM of three
independent experiments. The SEM is not shown for some
data points because it was smaller than the symbol. The
RGS3 and RGS3T groups are significantly lower than the
control group (p < 0.05), and the RGS3T group is significantly
lower than the RGS3 group (p < 0.05).BMC Cell Biology 2001, 2:21 http://www.biomedcentral.com/1471-2121/2/21
teins (Fig. 2). An RGS3-GST fusion protein was incubat-
ed with an 35S-Met-Gα -protein, and the amount of
labeled Gα -protein was determined using glutathione-
coupled beads to "pull down" the RGS3-GST/35S-Gα -
protein complex that was then separated and quantified
by SDS/PAGE (Fig. 2). More Gqα  was bound by RGS3
than any other protein, although its binding was not sig-
nificantly different from that of Gzα  and Giα  (p > 0.05).
Significant (p < 0.05) amounts of Gi2α , Gi1α , Goα , and
Gsα  also were bound but were not as high as Gqα , Gzα ,
and Gi3α . These results confirm our previous findings
that RGS3 interacts with Gqα  but also show that it has
significant interaction with all other Gα -proteins stud-
ied.
The findings of the current, and an earlier study [9],
demonstrate clearly that RGS3 suppresses GnRH recep-
tor signaling in a heterologous cell system. Because of the
evidence that the signal transduction pathway for GnRH
in gonadotropes involves the GnRH receptor, Gqα , phos-
pholipase Cβ , and cellular IP3 release [39,40], we deter-
mined the effect of RGS3 on GnRH-stimulated LH
secretion using adenoviral-mediated gene transfer in rat
pituitary cells (Fig. 3). In these experiments, we per-
formed a dose-response test that included three experi-
mental groups: uninfected, adeno-β  galactosidase, and
adeno-RGS3 infected. Adeno-β gal infection was used for
determination of the fraction of cells infected at each
dose of virus (Fig. 3, top panel) and as a control for the
effects of adeno-RGS3 on GnRH-stimulated LH secre-
tion (Fig. 3, middle panel). Cell viability, measured as
trypan blue exclusion, varied from 98.5–100.0% (Fig. 3,
top panel). The fraction of cells infected by the adenovi-
rus depended on viral dose (0–5.0 M.O.I.; 1 M.O.I. = 1 vi-
ral particle/pituitary cell) and ranged from about 2% (no
adenovirus) to 99.5% (5.0 M.O.I.). Adeno-β gal had no ef-
fect on LH secretion at any dose compared to the unin-
fected group (Fig. 3, middle panel). In contrast, an
inverse dose-related effect was observed between adeno-
RGS3 and GnRH-stimulated LH secretion (Fig. 3, bot-
tom panel). RGS3 0.2 M.O.I. was the lowest dose to in-
hibit LH secretion (p < 0.05), and 2.0 and 5.0 M.O.I.
exerted near complete inhibition of LH secretion; i.e. LH
concentrations in these two latter GnRH-treated groups
did not differ from their cohort controls (p > 0.05).
The profound inhibition of GnRH-stimulated LH secre-
tion observed in Fig. 3 required verification that RGS3
expression was induced by adeno-RGS3 infection. To ad-
dress this issue, we performed RGS3 immunoblots (Fig.
4) which showed an increase in RGS3 protein expression
in adeno-RGS3 (5.0 M.O.I.) infected pituitary cells as
compared to low to negligible levels of protein in the un-
infected and adeno-β gal infected groups.
As evidenced earlier, the molecular locus of RGS protein
action is thought to be the G protein α  subunit, specifi-
cally Gqα  in the case of GnRH receptor activation. The
results shown in Fig. 5 are consistent with this conclu-
sion: adeno-RGS3 infection of rat pituitary cells pro-
foundly suppressed GnRH-stimulated 3H-inositol
phosphate accumulation. These results are compatible
with a molecular site of action for RGS3 being at phos-
pholipase C or earlier in the signal transduction pathway.
Another experiment conducted to test the specificity and
molecular locus of RGS3 action in inhibiting GnRH-
stimulated LH secretion was treatment of adeno-RGS3
infected cells with an agent that increases intracellular
calcium (Fig. 6). Calcium is an established stimulator of
LH secretion that is thought to act at sites downstream of
phospholipase C [39,40]. Therefore, adeno-RGS3 infect-
ed pituitary cells were treated with a calcium ionophore
(A23187). Adeno-RSG3 inhibited LH secretion in the
GnRH-treated control group as expected (Fig. 6). How-
ever, the calcium ionphore stimulated LH secretion in
RGS3-expressing gonadotropes (Fig. 6), an effect that
would be expected if the RGS3 inhibition was exerted at
the level of the Gqα  protein.
Figure 2
In vitro binding of RGS3 to Gα  proteins. An RGS3-GST fusion
protein was incubated with 35S-Met-Gα  proteins, and glu-
tathione beads were used to "pull-down" the RGS3-GST/Gα
protein complex. The amount of 35S-Gα  protein bound was
determined by SDS/PAGE separation, and quantification
using a Phosphor imaging device. The data point for each G
protein is the fraction of its total cpm that were bound to
RGS3-GST fusion protein after subtraction of the cpm bound
to control GST fusion protein. Mean ± SEM of three inde-
pendent experiments. Gqα , Gzα , and Gi3α  were not signifi-
cantly different from the other Gα -proteins (p < 0.05) that,
in turn, were significantly higher than a group to which 35S-
Met alone was added (p < 0.05).BMC Cell Biology 2001, 2:21 http://www.biomedcentral.com/1471-2121/2/21
In two final control studies, we investigated the effect of
adeno-RGS3 on LH concentrations in pituitary cells and
on GnRH receptor binding (Fig. 7). In neither case did
RGS3 affect these parameters of gonadotrope function (p
> 0.05).
Discussion
The quantity of LH secreted by the anterior pituitary
gland is the outcome of an interaction between the
amount of hypothalamic GnRH secretion and the level of
gonadotrope responsiveness to GnRH [7]. Quantitative-
ly, gonadotrope responsiveness is more important than
the level of GnRH secretion; for example, during the es-
trogen-stimulated preovulatory surge of LH secretion in
the rat there is a 5-fold increase in GnRH secretion but a
50-fold increase in LH secretion [7]. Moreover, a quanti-
ty of GnRH that will evoke a normal preovulatory LH
surge during the period preceding ovulation will induce
only a small increase in LH secretion at other stages of
the estrous cycle [7]. Similarly, termination of the preo-
Figure 3
RGS3 inhibits GnRH-stimulated LH secretion. Rat anterior
pituitary cells were infected or not with adeno-β gal or
adeno-RGS3, and 72 h later treated with GnRH to stimulate
LH secretion. Upper panel: Adeno-β gal infection was used to
determine the fraction of total pituitary cells infected at each
dose of adenovirus. Cell viability was measured as trypan
blue exclusion. Middle panel: Adeno-β gal infection at various
doses was used to control for the effect of RGS3 on GnRH-
stimulated LH secretion. No dose of adeno-β gal had an effect
on LH release (p < 0.05). Bottom panel: Dose-response rela-
tionship between dose of adeno-RGS3 and GnRH-stimulated
LH secretion. Adeno-RGS3 doses of 0.2 M.O.I. and higher
significantly inhibited LH release (p < 0.05); doses of 2.0 and
5.0 M.O.I, suppressed LH secretion to levels that were not
significantly different from their cohorts not treated with
GnRH (p < 0.05). Data are mean ± SEM of three independent
experiments.
Figure 4
One immunoblot representative of 2 showing RGS3 expres-
sion in rat pituitary cells that remained uninfected (control)
or were infected with 5 M.O.I, adeno-β gal or of adeno-RGS3.
The ~70 kDa band is RGS3 (24); the bands at ~54 kDa are
non-specific because they appear in all 3 lanes.BMC Cell Biology 2001, 2:21 http://www.biomedcentral.com/1471-2121/2/21
Figure 5
3H-inositol phosphate accumulation stimulated by GnRH was
inhibited by RGS3. Pituitary cells were infected with adeno-
β gal or adeno-RGS3 (5 M.O.I.) and 72 h later were treated
with GnRH agonist (10-7 M for 1 h). Data presented are the
means ± SEM (n = 4). The letter a above the results of the
treatment groups indicates that a group is not statistically sig-
nificantly different (p > 0.05) from its control whereas the
letter b indicates difference (p < 0.05) from its control group.
Figure 6
Calcium influx stimulated LH secretion in rat pituitary cells
expressing RGS3. Calcium influx was achieved by calcium
ionophore (A23187) treatment (100 µM for 3 h) of pituitary
cells infected with 5 M.O.I, of adeno-RGS3. Adeno-RGS3 sig-
nificantly inhibited LH secretion stimulated by GnRH (p <
0.05) but not by calcium ionophore (p > 0.05).
Figure 7
Effect of RGS3 on LH content and GnRH receptor binding.
Pituitary cells were infected or not with adeno-RGS3 or
adeno-β gal (5 M.O.I.) and 72 h later were used for measure-
ment of LH content or of GnRH receptors. Upper panel: LH
content of pituitary cells was measured after repeated freez-
ing and thawing to release LH for measurement by RIA.
There were no significant differences among the groups (p >
0.05). Lower panel: Pituitary cell membranes were prepared
for measurement of GnRH receptors by binding to 125I-
GnRH-A. There were no significant differences among the
groups. Our earlier report that adeno-β gal (60 M.O.I.)
increased receptor binding by 100% (23) was not observed
here because of the lower dose of adeno-β gal (5 M.O.I.)
used. Data are mean ± SEM of three independent experi-
ments.BMC Cell Biology 2001, 2:21 http://www.biomedcentral.com/1471-2121/2/21
vulatory LH surge appears to be due to desensitization of
the gonadotrope to GnRH action; in the sheep, a de-
crease in LH secretion precedes the decrease in GnRH
secretion [41], whereas in the rat, although the decrease
in GnRH and LH secretion are co-incident [7], there is
evidence that the gonadotrope is already desensitized to
GnRH [42,43].
The mechanisms that alter gonadotrope responsiveness
to GnRH are unknown but they do not appear to be due
to GnRH receptor number or LH stores in the pituitary
gland [5–8]. However, the fraction of LH that is released
by a maximal dose of GnRH does vary positively with go-
nadotrope responsiveness [7], and elucidation of the
mechanisms altering the fraction of releasable LH is like-
ly to illuminate mechanisms of gonadotrope responsive-
ness to GnRH [44].
Two molecular loci recently have been implicated as po-
tential modulators of GnRH receptor signaling: one is
the receptor itself [23], and the other is the G protein that
transduces the signal generated by binding of the recep-
tor to its agonist [9]. With respect to the former locus, G
protein coupled receptor kinases (GRKs) act in an ago-
nist-specific manner to phosphorylate intracellular re-
gions of the receptor thus permitting β  arrestin binding
that sterically inhibits G protein association with the re-
ceptor [1,45]. We have reported previously that experi-
mental expression of GRKs in GnRH receptor-
expressing heterologous cells (COS-1) suppressed
GnRH-stimulated IP3 production, and that co-expres-
sion of GRK2 and β -arrestin 2 suppressed GnRH recep-
tor signaling more than that of either alone [23].
Stronger evidence that the GRK/β  arrestin paradigm
may play a role in regulating GnRH receptor signaling is
our recent finding that adenovirus-mediated gene trans-
fer of GRK2 into normal pituitary gonadotropes sup-
pressed GnRH-stimulated LH secretion and IP3
production [31]. However, no evidence has been present-
ed for a direct interaction between β -arrestin and the
GnRH receptor.
With respect to the G protein as a locus for modulation of
GnRH receptor signaling, we reported earlier that exper-
imental expression of RGS3 but not RGS1, 2, or 4 in
GnRH receptor expressing COS-1 cells suppressed
GnRH-stimulated IP3 production [9]. In the current re-
port, we present evidence strengthening the hypothesis
of a regulatory role for RGS3 in GnRH receptor signal-
ing: adenovirus-mediated expression of RGS3 in normal
pituitary gonadotropes profoundly inhibited GnRH-
stimulated LH secretion and 3H-inositol phosphate ac-
cumulation. Arguing for the specificity of this effect is the
stimulation of LH secretion by a calcium ionophore and
the failure of LH stores and GnRH-receptor binding to be
affected by RGS3. Moreover, our finding that GnRH-
stimulated IP3 production was inhibited supports the lo-
cus of the RGS3 effect as residing at phospholipase C or
earlier in the transduction pathway, most likely at the Gα
protein because of our studies both earlier [9] and here
showing that RGS3 binds Gqα   in vitro. Finally, the
stronger inhibitory effect of RGS3T than RGS 3 on COS
cell function was presumed to be true also for gonado-
trope function and therefore was not tested here.
The determination of RGS specificity for receptor-G pro-
tein pairs are currently unknown; i.e., we and others
have found that several RGSs interact with Gqα  but only
one, RGS3, has potent inhibitory activity on GnRH re-
ceptor signaling. For instance, RGS4 and RGS-GAIP [11],
RGS3 [9], RGS2 [46], and RGS7 (our unpublished find-
ings) all bind Gqα , the established G protein that trans-
duces GnRH receptor signaling [38]. Nevertheless,
RGS2 and 4 [9], and RGS-GAIP and RGS7 (our unpub-
lished data) are weak or null inhibitors of GnRH receptor
signaling. A recent report seems to have clarified this is-
sue: RGS4 must bind not only Gqα  but also selected Gq-
coupled receptors before it can inhibit receptor signaling
[47,48]. Based on this finding, we propose that RGS3's
binding to the GnRH receptor as well as to Gqα  accounts
for its specific inhibiting of GnRH receptor signaling.
Conclusions
The results of the current investigation as well as those
presented earlier [31] nominate two molecular mecha-
nisms as playing roles in setting the responsiveness level
of GnRH receptor signaling; i.e., the RGS3 system acts at
the G protein transducing step and the GRK/β  arrestin
system acts at the level of the receptor. Future studies
must address whether both, neither, or only one of these
mechanisms are physiologically relevant.
Materials and Methods
cDNA transfection of COS-1 cells and measurement of IP3 
production
cDNA representing the rat GnRH receptor was cloned
into pcDNA3 as described and validated previously
[22,23]. cDNAs representing RGS3 and RGS3T (RGS3
amino acids 314–519) were cloned into the eukaryotic
expression vector, rcCMV, as described [24]. COS-1 cells
cultured as detailed before [23] were co-transfected with
GnRH receptor cDNA and RGS3 or RGS3T cDNA using
Lipofectamine (Life Technologies, Gaithersburg, MD)
[23], and 72 h later, treated with 10-7 M GnRH-A for 0,
10, 20, or 30 sec before being collected for IP3 measure-
ments [22,23].
IP3 measurements were performed on COS-1 cell cy-
tosolic preparations using a radioreceptor assay in whichBMC Cell Biology 2001, 2:21 http://www.biomedcentral.com/1471-2121/2/21
IP3 and 3H-IP3 compete for binding to IP3 receptors pre-
pared from calf cerebellum membranes [22,23].
RGS3 binding of Gα -proteins in vitro
RGS3 protein fused to glutathione-S-transferase (RSG3-
GST fusion protein) was produced in the pGEX-5x-1 sys-
tem of Pharmacia as detailed previously [9]. 35S-Met la-
beled Gα -proteins were prepared in vitro using a
transcription/translation protocol [9]. cDNAs for Gqα
[25] and Gzα  [26] were obtained from M. I. Simon; for
Gsα  (ref. No. 63315) and Gi2α  (ref. No. 63311) were ob-
tained from the American Type Culture Collection
(ATCC); for Gα o [27] was obtained from Eva G. Neer; for
Gi1α , [28] from G. R. Post; and, for Gi3α  [29] from M. G.
Farquhar. Binding studies of recombinant RGS3-GST fu-
sion protein to 35S-Met-Gα -proteins were performed as
detailed [9]. Glutathione-coupled beads were used to se-
lect 35S-Gα  proteins bound to RGS3-GST, and were then
eluted for separation by SDS/PAGE [9]. The amount and
molecular size of 35S-Gα  protein were determined using
a Phosphor imaging device (Molecular Dynamics).
Preparation of Adeno-RGS3
Recombinant adenovirus containing RGS3 cDNA was
prepared using procedures previously described in detail
by Becker et al.[30] and by us [31]. Human RGS3 cDNA
[24] was restricted from the pRC/CMV vector with
EcoRI, and then subcloned into the corresponding site of
the pACCMVpLpa plasmid. The proper orientation of the
RGS3 cDNA was confirmed by nucleotide sequencing.
The procedure for preparation of the adenovirus was co-
transfection of a human embryonic kidney cell line (HEK
293) with the pACCMVpLpa plasmid and another plas-
mid (pJM17) containing most of the viral genome [30]. A
relatively rare recombination of the two plasmids occurs
in the HEK 293 cells that reconstitutes the adenoviral ge-
nome. The recombination event reconstituting adeno-
RGS3 was confirmed using PCR analysis to detect the
presence of RGS3 cDNA. Next, adeno-RGS3 was isolated
by clonal selection in HEK 293 cells followed by a second
PCR to confirm the presence of RGS3 cDNA. Finally,
large-scale amplification and titering of adeno-RGS3
was performed in HEK 293 cells. This virus preparation
was used for infection of rat pituitary cells [31].
Culture and infection of rat pituitary cells
Anterior pituitary glands were obtained from female
Charles River CD rats that were maintained in accord-
ance with the NIH Guide for the Care and Use of Labora-
tory Animals using an experimental protocol that had
been approved by the Institutional Animal Care and Use
Committee. The pituitaries were dispersed with trypsin
as described before [32]. The mono-dispersed cells were
plated into poly-L-lysine coated 60 mm plastic Petri
dishes in DMEM/10% gelding horse serum containing
10-9 M estradiol to optimize the GnRH-responsiveness of
the gonadotropes [33], and incubated overnight at 37°C
in 8% CO2-92% air.
Pituitary cells were infected using a volume of adeno-
RGS3 or adeno-β  galactosidase necessary to achieve the
chosen multiplicity of infection (M.O.I.) diluted to 0.3
ml; this was further diluted with 1.2 ml of TS buffer (8.0
gm/L NaCI, 380 mg/L KCl, 100 mg/L Na2HPO4, 3.0
gm/L Tris HCI, 200 mg/L CaCl2· 2H2O, 100 mg/L
MgCl2 · 6H2O; pH 7.4). The pituitary cell culture medi-
um was aspirated and replaced with the virus solution,
and the cells were incubated at 37°C in a CO2 incubator
for approximately 72 h.
Next, the cells were collected by trypsinization and
counted using a hemocytometer; then, they were
checked for viability using trypan blue [31]. The cells
were replated for 2 h at 37°C in DMEM -0.1% bovine se-
rum albumin (BSA) and subjected to x-gal staining for
determination of the fraction of cells infected by the virus
[31], or to stimulation by GnRH-A for measurement of
LH release.
GnRH-stimulated LH secretion
Pituitary cells that had been re-trypsinized 72 h after in-
fection and then replated (100,000 cells/well in a 24-
well poly-L-lysine coated plate) for a 2 h preincubation
were subsequently treated with a GnRH agonist (1 ml of
10-7M D-Ala6 – des Gly10 – GnRH ethylamide; GnRH-A,
Sigma, St. Louis, MO) or a calcium ionophore (A23187,
Sigma) for 3 h as described by Conn et al.[34]. The medi-
um was removed and centrifuged at 200 ×  g for 10 min to
pellet any detached cells. The supernatant solution was
either used immediately or stored at -20°C prior to RIA.
LH RIAs were performed using reagents and instruc-
tions provided by Dr. A. F. Parlow on behalf of the Na-
tional Hormone and Pituitary Program, National
Institute of Diabetes and Digestive and Kidney Diseases,
NIH. Rat LH (NIDDK-rLH-l-9) was radioiodinated, the
LH antiserum (NIDDK-anti-rLH-S-11) was prepared in
rabbits, and the reference standard was NIDDK-rLH-
RP3. The mean EC50 of the standard curves (n = 10) was
0.59 ng with a coefficient of variation of 4.4%.
GNRH-stimulated 3H-inositol phosphate accumulation in 
pituitary cells
Total [3H] inositol phosphate accumulation was deter-
mined in [3H] myoinositol-labeled pituitary cells as de-
scribed earlier [22]. At 48 h after infection of the
pituitary cells, the incubation medium was removed and
replaced with a balanced salt solution (10 mM Hepes,
pH7.4, 135 mM NaCI, 4.5 mM KCL, 1.5 mM CaCl2, 0.5
mM MgCL2, 1.0 mM NaH2PO4, 5.6 mM glucose, 0.3%BMC Cell Biology 2001, 2:21 http://www.biomedcentral.com/1471-2121/2/21
BSA, and 10-9M estradiol) containing 5 µCi of [3H]-my-
oinositol/ml of medium. After a further 24 h, the pitui-
tary cells were recovered by trypinization, counted, and
replated in balanced salt solution (400,000 – 500,000
cells/well in a 24-well plate) for a 2 h preincubation.
Then, the cells were stimulated with GnRH-A (10-7M for
one hr) in the presence of 5 mM LiCI. [3H]-inositol phos-
phate accumulation in the cells was then measured using
ion exchange chromatography followed by liquid scintil-
lation spectroscopy [22].
Immunoblots for RGS3
An antibody to hexa-histidine-tagged human RGS3T was
prepared in chickens. RGS3T [24] is the carboxy termi-
nal 206 amino acids (a.a. 314–519) of RGS3 and is repre-
sented by nt 1227–1847 of RGS3 cDNA (Genbank
Accession #U27655). To prepare hexa-histidine amino
terminally-tagged RGS3T, we modified RGS3T cDNA
[24] using PCR with primers containing restriction sites
(the 5' primer incorporated a Bam HI site, whereas the 3'
primer bore an Nde 1 site). The PCR product was then
cloned into the pET15b vector which carries an N-termi-
nal Histag sequence followed by BamH1 and Nde 1 clon-
ing sites (Novagen Inc., Madison, WI). The resulting
plasmid DNA was nucleotide-sequenced to confirm the
presence of RGS3T cDNA. The cDNA was then used to
transform E. coli of the BL21(DE3) strain. Protein induc-
tion was performed using isopropyl-β -D-thiogalacto-
pyranoside (IPTG) as described by Novagen Inc.
Inclusion bodies containing the protein were prepared
and then solubized in 6 M guanidine. The Histag RGS3T
protein was purified on a Ni2+ resin using a Pharmacia
Hi-Trap 1 ml Chelating Column (Pharmacia Biotech, Pis-
cataway, NJ).
Antibodies to Histag RGS3T protein were prepared in
chickens (Aves Labs, Inc., Tigard, OR). A chicken was in-
jected with 145 µg of RGS3T into the breast muscle on
four separate occasions; the first injection was in com-
plete Freund's adjuvant, whereas injections 2–4 were
made in a 1:1 dilution of complete and incomplete Fre-
und's adjuvant. One week after the last injection, 6 im-
mune eggs were collected, and the IgY fraction purified
from the 6 eggs as well as from 3 pre-immune eggs col-
lected from the same hen.
Immunoblots for RGS3 expression in pituitary cells were
performed as described previously by us [22,23]. In
brief, rat pituitary cells at 72 h after adeno-RGS3 infec-
tion (5 M.O.I.) were collected by trypsinization, homog-
enized, and a protein determination made. Fifty µg
protein samples were heated in SDS-PAGE sample buff-
er containing β -mercaptoethanol and then electro-
phoresed on a 10% SDS-polyacrylamide gel. Separated
proteins were electroblotted onto nylon membranes
(Millipore Corp., Bedford, MA) which were then incubat-
ed for 2 h in a blocking solution containing 5% non-fat
dry milk in phosphate buffered saline containing 0.02%
Tween-20. The primary antibody (chicken IgY, 62.5 µg/
ml) was diluted in blocking solution and incubated over-
night at 4°C with the nylon membrane. Blots were then
incubated for 2 h at room temperature in alkaline phos-
phatase-conjugated goat anti-chicken IgY (0.1 µg/ml di-
luted in blocking solution; Aves Labs, Tigard, OR). Color
development was achieved by incubating the membrane
in substrate [(5-bromo-4-chloro-3-indolyl phosphate-
nitrobluetetra-zolium chloride) (BCIP-NBT)].
Assay of LH contents in pituitary cells
For LH RIA measurements of cell contents, 1 ×  105 ante-
rior pituitary cells infected, or not, 72 h previously with
adeno-RGS3 or adeno-β gal were trypsinized and plated
for 2 h. LH was extracted from the cells [36] by removing
and discarding the medium and adding 1 ml extraction
buffer (150 mM NaCI, 50 mM Tris, 5 mM EDTA, and 1
mM bacitracin, pH 7.4) followed by freeze-thawing
twice. After centrifugation, the supernatant was removed
and subjected to LH RIA as described above.
Measurements of GnRH receptors by receptor radioassay 
(RRA)
About 3 ×  106 pituitary cells infected, or not, 72 h previ-
ously with adeno-β gal or adeno-RGS3 were trypsinized,
and cell membranes containing the GnRH receptors
were prepared by placing the cells in a Dounce homoge-
nizer (Kontes Co., Vineland, NJ) and disrupting them
with 30 strokes of the pestle. The cell membranes were
pelleted by centrifugation at 26,000 ×  g and then resus-
pended in 10 mM Tris buffer. The GnRH RRA on the
membranes was performed as described previously
[22,23]. Cell membranes and 1 ×  105 cpm [125I]GnRH-A
were incubated at 0°C for 90 min. Nonspecific binding
was determined as counts per min bound in the presence
of 10-6 M unlabeled GnRH-A. Bound and free [125I]Gn-
RH-A were separated by filtration. The filters were
counted by γ -scintillation spectrometry.
Data analysis
The results are presented as the mean ± SEM of at least
three independent experiments unless indicated other-
wise. The statistical tests were one-way or two-way anal-
yses of variance with significant differences (p < 0.05)
identified by the Student – Newman-Keuls method. Sta-
tistical analysis was performed using Sigma Stat Statisti-
cal Software for Windows (Jandel Scientific, San Rafael,
CA).
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